US EditionLarimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the publication of two new peer-reviewed articles detailing nonclinical data supporting the therapeutic potential of its investigational frataxin replacement therapy, nomlabofusp, for the treatment of Friedreich’s ataxia (FA). The publications, now available online, focus on nomlabofusp’s pharmacology, mechanism of action, and its impact on disease-relevant tissues. Titled…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
